The current stock price of IIN is 24.24 null. In the past month the price increased by 0.92%. In the past year, price increased by 8.55%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.61 | 222.19B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.86 | 210.17B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.15 | 144.97B | ||
| SYK | STRYKER CORP | 27.82 | 140.11B | ||
| BDX | BECTON DICKINSON AND CO | 14.24 | 58.61B | ||
| IDXX | IDEXX LABORATORIES INC | 56.05 | 56.44B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.4 | 49.82B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.9 | 39.51B | ||
| RMD | RESMED INC | 25.17 | 36.37B | ||
| DXCM | DEXCOM INC | 37.58 | 27.26B | ||
| PODD | INSULET CORP | 64.41 | 20.71B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.71 | 18.78B |
Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. The company is headquartered in Arden Hills, Minnesota and currently employs 873 full-time employees. The firm serves as a JDM partner to medical device original equipment manufacturers (OEMs) by designing, developing, engineering, manufacturing, packaging and distributing micro medical devices components and subassemblies for medical markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. The company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete catheter-based and body-worn devices for medical device manufacturers. The firm serves its market by offering medical device manufacturers, which have the capabilities to design, develop, manufacture, package and distribute medical devices. The company operates globally with facilities in Minnesota, Illinois, California, Singapore, Indonesia and Germany.
INTRICON CORP
1260 Red Fox Road
Arden Hills MINNESOTA 55112 US
CEO: Scott Longval
Employees: 873
Phone: 16516369770.0
Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. The company is headquartered in Arden Hills, Minnesota and currently employs 873 full-time employees. The firm serves as a JDM partner to medical device original equipment manufacturers (OEMs) by designing, developing, engineering, manufacturing, packaging and distributing micro medical devices components and subassemblies for medical markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. The company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete catheter-based and body-worn devices for medical device manufacturers. The firm serves its market by offering medical device manufacturers, which have the capabilities to design, develop, manufacture, package and distribute medical devices. The company operates globally with facilities in Minnesota, Illinois, California, Singapore, Indonesia and Germany.
The current stock price of IIN is 24.24 null. The price increased by 0.04% in the last trading session.
IIN does not pay a dividend.
IIN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
The Revenue of INTRICON CORP (IIN) is expected to grow by 10.43% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
INTRICON CORP (IIN) has a market capitalization of 225.49M null. This makes IIN a Micro Cap stock.
INTRICON CORP (IIN) will report earnings on 2022-08-08.
ChartMill assigns a technical rating of 7 / 10 to IIN. When comparing the yearly performance of all stocks, IIN is one of the better performing stocks in the market, outperforming 94.95% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to IIN. IIN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months IIN reported a non-GAAP Earnings per Share(EPS) of 0.55. The EPS increased by 1200% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1.17% | ||
| ROA | -1.17% | ||
| ROE | 1.03% | ||
| Debt/Equity | 0 |
5 analysts have analysed IIN and the average price target is 25.5 null. This implies a price increase of 5.2% is expected in the next year compared to the current price of 24.24.
For the next year, analysts expect an EPS growth of -13.69% and a revenue growth 10.43% for IIN